Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-06-30T22:27:06.140Z Has data issue: false hasContentIssue false
  • English
  • Français

Defining the optimal historical control group for a phase 1 trial of mesenchymal stromal cell delivery through cardiopulmonary bypass in neonates and infants

Published online by Cambridge University Press:  22 August 2022

Kei Kobayashi Open the ORCID record for Kei Kobayashi [Opens in a new window] ,
Tessa Higgins ,
Christopher Liu ,
Mobolanle Ayodeji ,
Gil Wernovsky ,
Richard A. Jonas  and
Nobuyuki Ishibashi
Kei Kobayashi
Affiliation:
Center for Neuroscience Research and Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, Washington, DC, USA Children’s National Heart Institute, Children’s National Hospital, Washington, DC, USA
Tessa Higgins
Affiliation:
Center for Neuroscience Research and Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, Washington, DC, USA The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
Christopher Liu
Affiliation:
Center for Neuroscience Research and Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, Washington, DC, USA Virginia Commonwealth University School of Medicine, Richmond, VA, USA
Mobolanle Ayodeji
Affiliation:
Center for Neuroscience Research and Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, Washington, DC, USA
Gil Wernovsky
Affiliation:
Children’s National Heart Institute, Children’s National Hospital, Washington, DC, USA The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
Richard A. Jonas
Affiliation:
Center for Neuroscience Research and Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, Washington, DC, USA Children’s National Heart Institute, Children’s National Hospital, Washington, DC, USA The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
Nobuyuki Ishibashi*
Affiliation:
Center for Neuroscience Research and Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, Washington, DC, USA Children’s National Heart Institute, Children’s National Hospital, Washington, DC, USA The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
*
Author for correspondence: Nobuyuki Ishibashi, MD, Children’s National Hospital, 111 Michigan Avenue, NW, Washington, DC, 20010, USA. Tel: +1 202 476 2388. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

The Mesenchymal Stromal Cell Delivery through Cardiopulmonary Bypass in Pediatric Cardiac Surgery study is a prospective, open-label, single-centre, dose-escalation phase 1 trial assessing the safety/feasibility of delivering mesenchymal stromal cells to neonates/infants during cardiac surgery. Outcomes will be compared with historical data from a similar population. We aim to define an optimal control group for use in the Mesenchymal Stromal Cell Delivery through Cardiopulmonary Bypass in Pediatric Cardiac Surgery trial.

Methods:

Consecutive patients who underwent a two-ventricle repair without aortic arch reconstruction within the first 6 months of life between 2015 and 2020 were studied using the same inclusion/exclusion criteria as the Phase 1 Mesenchymal Stromal Cell Delivery through Cardiopulmonary Bypass in Pediatric Cardiac Surgery trial (n = 169). Patients were allocated into one of three diagnostic groups: ventricular septal defect type, Tetralogy of Fallot type, and transposition of the great arteries type. To determine era effect, patients were analysed in two groups: Group A (2015–2017) and B (2018–2020). In addition to biological markers, three post-operative scoring methods (inotropic and vasoactive-inotropic scores and the Pediatric Risk of Mortality-III) were assessed.

Results:

All values for three scoring systems were consistent with complexity of cardiac anomalies. Max inotropic and vasoactive-inotropic scores demonstrated significant differences between all diagnosis groups, confirming high sensitivity. Despite no differences in surgical factors between era groups, we observed lower inotropic and vasoactive-inotropic scores in group B, consistent with improved post-operative course in recent years at our centre.

Conclusions:

Our studies confirm max inotropic and vasoactive-inotropic scores as important quantitative measures after neonatal/infant cardiac surgery. Clinical outcomes should be compared within diagnostic groupings. The optimal control group should include only patients from a recent era. This initial study will help to determine the sample size of future efficacy/effectiveness studies.

Keywords

CHDpatient outcome assessmentclinical trial
Type
Original Article
Information
Cardiology in the Young , Volume 33 , Issue 9 , September 2023 , pp. 1523 - 1528
Check for updates
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gaynor, JW, Stopp, C, Wypij, D, et al. Neurodevelopmental outcomes after cardiac surgery in infancy. Pediatrics 2015; 135: 816–825.10.1542/peds.2014-3825CrossRefGoogle ScholarPubMed
Wernovsky, G, Licht, DJ. Neurodevelopmental outcomes in children with congenital heart disease-what can we impact? Pediatr Crit Care Med 2016; 17: S232–242.10.1097/PCC.0000000000000800CrossRefGoogle ScholarPubMed
Marelli, A, Miller, SP, Marino, BS, Jefferson, AL, Newburger, JW. Brain in congenital heart disease across the lifespan. Circulation 2016; 133: 1951–1962.10.1161/CIRCULATIONAHA.115.019881CrossRefGoogle ScholarPubMed
Eckert, MA, Vu, Q, Xie, K, et al. Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. J Cereb Blood Flow Metab 2013; 33: 1322–1334.10.1038/jcbfm.2013.91CrossRefGoogle ScholarPubMed
Bernardo, ME, Fibbe, WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013; 13: 392–402.10.1016/j.stem.2013.09.006CrossRefGoogle ScholarPubMed
van Velthoven, CTJ, Sheldon, RA, Kavelaars, A, et al. Mesenchymal stem cell transplantation attenuates brain injury after neonatal stroke. Stroke 2013; 44: 1426–1432.10.1161/STROKEAHA.111.000326CrossRefGoogle ScholarPubMed
le Blanc, K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003; 5: 485–489.10.1080/14653240310003611CrossRefGoogle ScholarPubMed
Krampera, M, Glennie, S, Dyson, J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722–3729.10.1182/blood-2002-07-2104CrossRefGoogle ScholarPubMed
Hare, JM, Traverse, JH, Henry, TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54: 2277–2286.10.1016/j.jacc.2009.06.055CrossRefGoogle ScholarPubMed
Bernstein, HS, Srivastava, D. Stem cell therapy for cardiac disease. Pediatr Res 2012; 71: 491–499.10.1038/pr.2011.61CrossRefGoogle ScholarPubMed
Gotts, JE, Matthay, MA. Mesenchymal stem cells and acute lung injury. Crit Care Clin 2011; 27: 719–733.10.1016/j.ccc.2011.04.004CrossRefGoogle ScholarPubMed
Humphreys, BD, Bonventre, JV. Mesenchymal stem cells in acute kidney injury. Annu Rev Med 2008; 59: 311–325.10.1146/annurev.med.59.061506.154239CrossRefGoogle ScholarPubMed
Zhu, X-Y, Lerman, A, Lerman, LO. Concise review: mesenchymal stem cell treatment for ischemic kidney disease. Stem Cells 2013; 31: 1731–1736.10.1002/stem.1449CrossRefGoogle ScholarPubMed
Maeda, T, Briggs, CM, Datar, A, et al. Influence of administration of mesenchymal stromal cell on pediatric oxygenator performance and inflammatory response. JTCVS Open 2021; 5: 99–107.10.1016/j.xjon.2021.02.003CrossRefGoogle ScholarPubMed
Maeda, T, Sarkislali, K, Leonetti, C, et al. Impact of mesenchymal stromal cell delivery through cardiopulmonary bypass on postnatal neurogenesis. Ann Thorac Surg 2020; 109: 1274–1281.10.1016/j.athoracsur.2019.08.036CrossRefGoogle ScholarPubMed
Overman, DM, Jacobs, JP, Prager, RL, et al. Report from the Society of Thoracic Surgeons National Database Workforce: clarifying the definition of operative mortality. World J Pediatr Congenit Heart Surg. 2013; 4: 10–12.10.1177/2150135112461924CrossRefGoogle Scholar
Wernovsky, G, Wypij, D, Jonas, RA, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. Circulation 1995; 92: 2226–2235.10.1161/01.CIR.92.8.2226CrossRefGoogle ScholarPubMed
Gaies, MG, Gurney, JG, Yen, AH, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med 2010; 11: 234–328.10.1097/PCC.0b013e3181b806fcCrossRefGoogle ScholarPubMed
Pollack, MM, Patel, KM, Ruttimann, UE. PRISM III: an updated pediatric risk of mortality score. Crit Care Med 1996; 24: 743–752.10.1097/00003246-199605000-00004CrossRefGoogle ScholarPubMed
Pollack, MM, Holubkov, R, Funai, T, et al. Simultaneous prediction of new morbidity, mortality, and survival without new morbidity from pediatric intensive care. Crit Care Med 2015; 43: 1699–1709.10.1097/CCM.0000000000001081CrossRefGoogle ScholarPubMed
Russell, RA, Rettiganti, M, Brundage, N, Jeffries, HE, Gupta, P. Performance of pediatric risk of mortality score among critically ill children with heart disease. World J Pediatr Congenit Heart Surg 2017; 8: 427–434.10.1177/2150135117704656CrossRefGoogle ScholarPubMed
Berger, JT, Holubkov, R, Reeder, R, et al. Morbidity and mortality prediction in pediatric heart surgery: physiological profiles and surgical complexity. J Thorac Cardiovasc Surg 2017; 154: 620–628.10.1016/j.jtcvs.2017.01.050CrossRefGoogle ScholarPubMed
Nathan, M, Karamichalis, JM, Liu, H, et al. Intraoperative adverse events can be compensated by technical performance in neonates and infants after cardiac surgery: a prospective study. J Thorac Cardiovasc Surg 2011; 142: 1098–1107.10.1016/j.jtcvs.2011.07.003CrossRefGoogle ScholarPubMed
Karamichalis, JM, del Nido, PJ, Thiagarajan, RR, et al. Early postoperative severity of illness predicts outcomes after the stage I Norwood procedure. Ann Thorac Surg 2011; 92: 660–665.10.1016/j.athoracsur.2011.03.086CrossRefGoogle ScholarPubMed
Basaran, M, Sever, K, Kafali, E, et al. Serum lactate level has prognostic significance after pediatric cardiac surgery. J Cardiothorac Vasc Anesth 2006; 20: 43–47.10.1053/j.jvca.2004.10.010CrossRefGoogle ScholarPubMed
Kalyanaraman, M, DeCampli, WM, Campbell, AI, et al. Serial blood lactate levels as a predictor of mortality in children after cardiopulmonary bypass surgery. Pediatr Crit Care Med 2008; 9: 285–288.10.1097/PCC.0b013e31816c6f31CrossRefGoogle ScholarPubMed
Gaies, MG, Jeffries, HE, Niebler, RA, et al. After infant cardiac surgery: an analysis from the pediatric cardiac critical care consortium (PC4) and virtual PICU system registries. Pediatr Crit Care Med 2014; 15: 529–537.10.1097/PCC.0000000000000153CrossRefGoogle Scholar
Pasquali, SK, Jacobs, JP, He, X, et al. The complex relationship between center volume and outcome in patients undergoing the norwood operation. Ann Thorac Surg 2012; 93: 1556–1562.10.1016/j.athoracsur.2011.07.081CrossRefGoogle ScholarPubMed
Anderson, BR, Ciarleglio, AJ, Cohen, DJ, et al. The Norwood operation: relative effects of surgeon and institutional volumes on outcomes and resource utilization. Cardiol Young 2016; 26: 683–692.10.1017/S1047951115001031CrossRefGoogle ScholarPubMed
Anderson, BR, Wallace, AS, Hill, KD, et al. Association of surgeon age and experience with congenital heart surgery outcomes. Circ Cardiovasc Qual Outcomes 2017; 10: e003533.10.1161/CIRCOUTCOMES.117.003533CrossRefGoogle ScholarPubMed
Gaies, M, Cooper, DS, Tabbutt, S, et al. Collaborative quality improvement in the cardiac intensive care unit: development of the Paediatric Cardiac Critical Care Consortium (PC4). Cardiol Young 2015; 25: 951–957.10.1017/S1047951114001450CrossRefGoogle ScholarPubMed
Supplementary material: File

Kobayashi et al. supplementary material

Tables S1-S4

Download Kobayashi et al. supplementary material(File)
File 25.4 KB